Novartis to Halt Development of Ionis-Derived Heart Disease Therapy Following Clinical Trial Failure
Novartis (NVS) has decided to largely abandon the development of an RNA-targeting therapy for heart disease, which was originally discovered by Ionis Pharmaceuticals (IONS). The decision follows a significant setback in a late-stage clinical trial conducted last September. The move marks a strategic pivot for Novartis as it moves away from this specific therapeutic candidate. For Ionis Pharmaceuticals, the failure of this high-profile collaboration highlights the inherent risks associated with RNA-targeting drug development and its impact on partnership pipelines.